Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk
Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn about a recent article by Faizan Mazhar et al, adding:
“Inflammation vs cholesterol: which residual risk matters most in ASCVD?
A large real-world study explored how cholesterol risk (LDL-C) and inflammatory risk (hsCRP) relate to cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease (ASCVD).
Researchers analyzed 39,638 patients with ASCVD in routine healthcare in Stockholm between 2007–2021. Patients were stratified into four groups based on LDL-C greater than or equal to 1.8 mmol/L (approximately 70 mg/dL) and hsCRP greater than or equal to 2 mg/L:
- Low risk
- High cholesterol risk
- High inflammatory risk
- Combined high cholesterol plus inflammatory risk
The primary endpoint was major adverse cardiovascular events (MACE), with additional outcomes including cardiovascular mortality, all-cause mortality, and heart failure hospitalization.
Key findings
Inflammatory risk mattered more than cholesterol alone!!!
Patients with high inflammatory risk (hsCRP greater than or equal to 2 mg/L) had significantly higher rates of:
- MACE
- cardiovascular mortality
- all-cause mortality
- heart failure hospitalization
High cholesterol alone was associated with only a modest increase in MACE and was not strongly linked to other adverse outcomes.
Another striking observation: approximately 39% of ASCVD patients were not receiving lipid-lowering therapy, highlighting persistent gaps in secondary prevention in routine care.
Why this matters
The study reinforces a growing concept in cardiometabolic medicine:
Residual inflammatory risk remains a major driver of cardiovascular events even when cholesterol is treated.
This helps explain why therapies targeting inflammation (e.g., colchicine, IL-1 pathways) are increasingly explored alongside lipid-lowering strategies.
Take-home message
ASCVD risk is not just about LDL-C.
In real-world populations, inflammation appears to be an equally important — and often overlooked — driver of recurrent cardiovascular events.
Future prevention strategies will likely need to target both cholesterol and inflammation. ”
Title: Inflammatory and cholesterol risks and rates of major cardiovascular events among patients with atherosclerotic cardiovascular disease in routine care
Authors: Faizan Mazhar, Davide Capodanno, Paul Hjemdahl, Arvid Sjölander, Sofia Gerward, Jimmi Mathisen, Oscar Plunde, Vijay Kunadian, Tomas Jernberg, Juan-Jesus Carrero
Read the Full Article on European Heart Journal Open
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS